Nair Sandhya, Desai Srividya, Poonacha Nethravathi, Vipra Aradhana, Sharma Umender
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India.
GangaGen Biotechnologies Pvt. Ltd., Yeshwantpur, Bangalore, India
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7280-7289. doi: 10.1128/AAC.01118-16. Print 2016 Dec.
P128 is an antistaphylococcal protein, comprising a cell wall-degrading enzymatic region and a Staphylococcus-specific binding region, which possesses specific and potent bactericidal activity against sensitive and drug-resistant strains of Staphylococcus aureus To explore P128's ability to kill S. aureus in a range of environments relevant to clinical infection, we investigated the anti-S. aureus activity of P128 alone and in combination with standard-of-care antibiotics on planktonic and biofilm-embedded cells. P128 was found to have potent antibiofilm activity on preformed S. aureus biofilms as detected by CFU reduction and a colorimetric minimum biofilm inhibitory concentration (MBIC) assay. Scanning electron microscopic images of biofilms formed on the surfaces of microtiter plates and on catheters showed that P128 at low concentrations could destroy the biofilm structure and lyse the cells. When it was tested in combination with antibiotics which are known to be poor inhibitors of S. aureus in biofilms, such as vancomycin, gentamicin, ciprofloxacin, linezolid, and daptomycin, P128 showed highly synergistic antibiofilm activity that resulted in much reduced MBIC values for P128 and the individual antibiotics. The synergistic effect was seen for both sensitive and resistant isolates of S. aureus Additionally, in an in vitro mixed-biofilm model mimicking the wound infection environment, P128 was able to prevent biofilm formation by virtue of its anti-Staphylococcus activity. The potent S. aureus biofilm-inhibiting activity of P128 both alone and in combination with antibiotics is an encouraging sign for the development of P128 for treatment of complicated S. aureus infections involving biofilms.
P128是一种抗葡萄球菌蛋白,由一个细胞壁降解酶区域和一个葡萄球菌特异性结合区域组成,对金黄色葡萄球菌的敏感菌株和耐药菌株具有特异性且强效的杀菌活性。为了探究P128在一系列与临床感染相关的环境中杀死金黄色葡萄球菌的能力,我们研究了P128单独以及与标准护理抗生素联合对浮游菌和生物膜包裹菌的抗金黄色葡萄球菌活性。通过菌落形成单位(CFU)减少和比色法最低生物膜抑制浓度(MBIC)测定发现,P128对预先形成的金黄色葡萄球菌生物膜具有强效的抗生物膜活性。在微量滴定板表面和导管上形成的生物膜的扫描电子显微镜图像显示,低浓度的P128可以破坏生物膜结构并裂解细胞。当与已知对生物膜中金黄色葡萄球菌抑制作用较差的抗生素(如万古霉素、庆大霉素、环丙沙星、利奈唑胺和达托霉素)联合测试时,P128表现出高度协同的抗生物膜活性,导致P128和各单独抗生素的MBIC值大幅降低。金黄色葡萄球菌的敏感和耐药分离株均出现了协同效应。此外,在模拟伤口感染环境的体外混合生物膜模型中,P128凭借其抗葡萄球菌活性能够预防生物膜形成。P128单独以及与抗生素联合时对金黄色葡萄球菌生物膜的强效抑制活性,对于开发P128用于治疗涉及生物膜的复杂金黄色葡萄球菌感染来说是一个令人鼓舞的迹象。